Skip to main content

stock

EIKN · Eikon Therapeutics, Inc.

What Eikon Therapeutics, Inc. reports to the SEC, read from its filings.

Open in the app

Price

The live EIKN price and today's change.

Sign in to see this

Chart

Thirty days of daily bars, with signal levels drawn on them.

Sign in to see this

Signals

The latest signal group Nakagai's scanner recorded on EIKN.

Sign in to see this

Options positioning

Gamma exposure levels from the options market.

Sign in to see this

Technicals

Trend, momentum and volatility gauges per timeframe.

Sign in to see this

What it is

Industry
Biological Products, (No Diagnostic Substances) (SIC 2836)
Filer (SEC EDGAR)
EDGAR filing index
Shares outstanding
54,165,030 as of 2026-08-03 (XBRL frame CY2026Q2I)

Key stats

Valuation

P/E
Locked
P/S
Locked
P/B
Locked
Enterprise value
Locked
EV/EBIT
Locked
FCF yield
Locked

Margins

Gross
—
Operating
—
Net
—

Returns

ROE
—
ROA
—

Health

Current ratio
9.9x
Debt/equity
—

Deep value

NCAV
$233.91M
NCAV per share
$4.32
Price/NCAV
Locked
NNWC
-$170.46M
NNWC per share
-$3.15
Price/NNWC
Locked

Valuation and the price multiples are built on the live price. Trailing twelve months to —; balance sheet at 2026-06-30.

Sign in to see this

Debt is long-term debt and its current portion. Commercial paper and short-term borrowings are not counted.

Results

Period endRevenue (not reported by this company)Gross profit (not reported by this company)Operating incomeNet incomeFiling
2026-06-30—Revenue: unreported by this company.—Gross profit: unreported by this company.-$93.39M-$88.41M
10-Q filed 2026-08-13
2026-03-31—Revenue: unreported by this company.—Gross profit: unreported by this company.-$87.34M-$82.96M
10-Q filed 2026-08-13
Assembled from more than one filing; the filing above is only the newest of them.
2025-06-30—Revenue: unreported by this company.—Gross profit: unreported by this company.-$109.64M-$105.21M
10-Q filed 2026-08-13
2025-03-31—Revenue: unreported by this company.—Gross profit: unreported by this company.-$71.38M-$68.24M
10-Q filed 2026-08-13
Assembled from more than one filing; the filing above is only the newest of them.
Assets
$779.57M
Equity
$466.50M

Balance as of 2026-06-30.

Ten years

No annual results reported by SEC for this filer.

Company filings

1 offering filing in 12 months

events

  • Regulation FD disclosure

    Regulation FD disclosure
    Aug 138-K
  • Results

    Results
    Aug 138-K
  • Executive or director change

    Executive or director change
    Aug 38-K
  • Executive or director change

    Executive or director change
    Jun 108-K
  • Regulation FD disclosure, Other event

    Regulation FD disclosureOther event
    Jun 18-K
  • Results, Regulation FD disclosure

    ResultsRegulation FD disclosure
    May 118-K

5% owners ()

Insiders, politicians and funds

Insider trades, last 90 days

  • Column Group IV GP, LP

    10% owner

    Buy$1,031,045

    Sep 8, 4:33 PM ET

All insider trades for EIKN

Politician trades, last 90 days

No politician trades filed in the last 90 days.

Funds

All funds

News

Stories that named EIKN, and the market events around them.

Sign in to see this

Board

Recent signals

Signals open up here once a member has posted about EIKN.

Signals are informational.

Posts · 0

No posts yet.

Be the first to say something about EIKN.

nakagai

Signals on EIKN come from a rule, not a model.

Nakagai’s scanner records a signal the moment a strategy’s rule matches on the bars. Members read those signals on their own desk, where an agent journals the tape and briefs them in plain English.

Members post on the EIKN board

This page is not financial advice. Trade at your own judgment and risk. Read the terms that govern posting here.

Eikon Therapeutics, Inc. (EIKN): SEC filings, financials and insider trades · Nakagai